Literature DB >> 35558352

Effect of Jejunal Administration on Tacrolimus Trough Concentrations in a Pediatric Liver Transplant Recipient.

Alexandra Aldieri1, Esther Bae1, Mary Moss Chandran1.   

Abstract

Maintenance immunosuppression regimens containing calcineurin inhibitors, specifically tacrolimus, are standard of care for rejection prevention in pediatric liver transplantation. Challenges with tacrolimus administration are common with pediatric patients, and guidance for non-oral, enteral administration of tacrolimus is limited. We report the case of an 11-year-old male orthotopic liver transplant recipient with a history of malnutrition requiring a jejunostomy tube (J-tube) for enteral nutrition and medication administration post-transplantation. Tacrolimus was initially given orally, and then transitioned to J-tube administration for 10 days. Tacrolimus trough concentrations declined significantly following conversion to J-tube administration and remained subtherapeutic despite a 3-fold dose increase. Once transitioned back to the oral route, trough concentrations became supratherapeutic requiring dose reductions until goal concentrations were achieved. This case demonstrates reduced bioavailability and need for increased dosing, when tacrolimus is administered through a J-tube. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2022.

Entities:  

Keywords:  adolescent; biological availability; immunosuppression; jejunostomy; tacrolimus; transplantation

Year:  2022        PMID: 35558352      PMCID: PMC9088433          DOI: 10.5863/1551-6776-27.4.390

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  20 in total

1.  Oral absorption of FK506 in rats.

Authors:  A Kagayama; S Tanimoto; J Fujisaki; A Kaibara; K Ohara; K Iwasaki; Y Hirano; T Hata
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

2.  The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group.

Authors:  Mirko Koziolek; Stefano Alcaro; Patrick Augustijns; Abdul W Basit; Michael Grimm; Bart Hens; Caroline L Hoad; Philipp Jedamzik; Christine M Madla; Marc Maliepaard; Luca Marciani; Annalisa Maruca; Neil Parrott; Petr Pávek; Christopher J H Porter; Christos Reppas; Diana van Riet-Nales; Jari Rubbens; Marina Statelova; Natalie L Trevaskis; Kateřina Valentová; Maria Vertzoni; Dubravka Vitali Čepo; Maura Corsetti
Journal:  Eur J Pharm Sci       Date:  2019-04-08       Impact factor: 4.384

Review 3.  Duct-to-duct biliary reconstruction in pediatric split-liver transplantation.

Authors:  Cahit Yilmaz; Can A Karaca; Rasim Ferecov; Zaza Iakobadze; Kamil Kilic; Adnan Tosun; Murat Kilic
Journal:  Liver Transpl       Date:  2018-02-12       Impact factor: 5.799

4.  Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case report.

Authors:  M Kelley; A Jain; R Kashyap; M Orloff; P Abt; K Wrobble; R Venkataramanan; A Bozorgzadeh
Journal:  Transplant Proc       Date:  2005-09       Impact factor: 1.066

5.  Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation.

Authors:  T Hasegawa; K Nara; T Kimura; H Soh; T Sasaki; T Azuma; A Okada
Journal:  Pediatr Transplant       Date:  2001-06

6.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.

Authors:  K A Birdwell; B Decker; J M Barbarino; J F Peterson; C M Stein; W Sadee; D Wang; A A Vinks; Y He; J J Swen; J S Leeder; Rhn van Schaik; K E Thummel; T E Klein; K E Caudle; I A M MacPhee
Journal:  Clin Pharmacol Ther       Date:  2015-06-03       Impact factor: 6.875

7.  Choledochoduodenostomy is a safe alternative to Roux-en-Y choledochojejunostomy for biliary reconstruction in liver transplantation.

Authors:  William Bennet; Michael A Zimmerman; Jeffrey Campsen; Mercedes Susan Mandell; Tom Bak; Michael Wachs; Igal Kam
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

8.  Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children.

Authors:  R Reding; P E Wallemacq; M E Lamy; J Rahier; C Sempoux; B Debande; J Jamart; A Barker; E Sokal; J De Ville de Goyet
Journal:  Transplantation       Date:  1994-01       Impact factor: 4.939

Review 9.  Surface area of the digestive tract - revisited.

Authors:  Herbert F Helander; Lars Fändriks
Journal:  Scand J Gastroenterol       Date:  2014-04-02       Impact factor: 2.423

Review 10.  Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients.

Authors:  Kwaku Marfo; Jerry Altshuler; Amy Lu
Journal:  Pharmaceutics       Date:  2010-09-09       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.